Use when packaging AAAI code, data, multimedia appendices, technical appendices, reproducibility evidence, and post-acceptance artifact releases without violating double-blind or immutable-supplement rules.
日本語の概要は準備中です。原文の説明を表示しています。
Use when targeting Environmental Health Perspectives or deciding whether an environmental-health manuscript fits this venue. Encodes the journal's fit, the public-health-relevance and methodological-rigor bar, epidemiological/toxicological expectations, house style, official-submission re-check, and desk-reject heuristics.
インストールする前に、エージェントに与えられる指示の中身を確認できます。
Environmental Health Perspectives (EHP) is a peer-reviewed environmental-health journal published with support from the U.S. National Institute of Environmental Health Sciences (NIEHS), connecting environmental exposures to human health with strong public-health and policy relevance. Its defining expectation is public-health significance backed by rigorous epidemiology or toxicology: a study whose findings inform protection of human health and sit within a public-health and regulatory context. Relative to Environment International's broader environmental-science-plus-health scope, EHP is framed around the population-health and policy mission and holds an explicit standard for transparency and reproducibility. A purely environmental-chemistry or mechanistic study with no clear human-health and public-health implication is a weak fit. This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current author guidelines. Before submitting, re-check the live EHP submission guidance.
../../resources/source-basis.md and
../../resources/official-source-map.md; start from the official-source anchors, then cite
the current EHP page you checked.environment-international.environmental-pollution.the-lancet.nature-sustainability.environmental-science-and-technology.[Fit] High / Medium / Low (one-line reason)
[Target] Environmental Health Perspectives
[Topic tags] <2–3 closest environmental-health topics>
[Public-health significance] <how the finding informs human-health protection / policy>
[Method/evidence] <does epi/tox rigor + transparency + proportionate claims clear EHP's bar?>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / reporting guideline / ethics / data-reproducibility policy / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>
まだレビューはありません。使ってみた感想をお寄せください。
概要と使いどころ
Use when packaging AAAI code, data, multimedia appendices, technical appendices, reproducibility evidence, and post-acceptance artifact releases without violating double-blind or immutable-supplement rules.
日本語の概要は準備中です。原文の説明を表示しています。
Use when drafting an AAAI author response (rebuttal) under the single short character-limited author-feedback window, the no-URL rule, no-new-results guidance, AI-generated-review handling, and the AAAI two-phase review process where Phase-2 papers receive one feedback round before SPC/AC discussion.
日本語の概要は準備中です。原文の説明を表示しています。
Use when preparing an accepted AAAI paper for camera-ready source submission to AAAI Press, including proceedings page limits, two-column template compliance, copyright transfer, purchased extra technical pages, deanonymization, registration, oral or poster presentation, and final public artifact release.
日本語の概要は準備中です。原文の説明を表示しています。
Use when designing or auditing AAAI experiments for the broad-AI program committee, including baselines, ablations, statistical significance, robustness, human evaluation, AI-for-Social-Impact and alignment/safety evidence, compute and cost reporting, and reproducibility-checklist alignment for Phase-1 survival.
日本語の概要は準備中です。原文の説明を表示しています。
Use when positioning an AAAI paper's novelty against archival work, contemporaneous arXiv or workshop papers, and AAAI/IJCAI/NeurIPS/ICML/ICLR neighbors across the broad AI scope, while staying inside AAAI's dual-submission and AI-as-source policy constraints and writing a related-work section legible to non-specialist reviewers.
日本語の概要は準備中です。原文の説明を表示しています。
Use when strengthening an AAAI paper's reproducibility checklist (placed after references), experimental traceability, seed and hyperparameter reporting, compute and cost disclosure, dataset access and licensing, code/data ZIP readiness, and the claim-to-evidence map that Phase-1 reviewers use to judge rigor across AAAI's broad AI scope.
日本語の概要は準備中です。原文の説明を表示しています。